trans-3-hexenoyl raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-16. Anything still debated is marked as such rather than presented as settled.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Selectivity of a cyclodextrin phase is dependent on two key factors namely the size and structure of the analyte since it is based on a simple fit-unfit geometric criteria. An aromatic ring or cycloalkyl ring should be attached near the stereogenic center of the analyte. Substituents at or near the analyte chiral center must be able to interact with the hydroxyl groups at the entrance of the CD cavity through H-bonding. α-Cyclodextrin holds small aromatic molecules, whereas β-cyclodextrin incorporates both naphthyl groups and substituted phenyl groups. The aqueous compatibility of CD and its unique molecular structure make the CD- bonded phase highly suitable for use in chiral HPLC analysis of drugs. One further benefit of CD is that they are generally less expensive than the other CSPs. Some of the major shortcomings of CD CSPs is that it is limited to compounds that can enter into CD cavity, minor structural changes in analyte leads to unpredictable effect on resolution, often poor efficiency and cannot invert elution order.
Brachytherapy is used to place a sealed radioactive source inside or near the body to treat cancer, such as prostate cancer. Afterloading brachytherapy is often combined with teletherapy, which is external radiation delivered from a greater distance than brachytherapy. It is not classified as a nuclear medicine procedure, although like nuclear medicine, it uses the radiation emitted by radionuclides. After initial interest in brachytherapy in the early 20th century, its use declined in the mid-20th century because of the radiation exposure to physicians from manual handling of the radiation sources. It was not until the development of remote-controlled afterloading systems and the use of new radiation sources in the 1950s and 1960s that the risk of unnecessary radiation exposure to physicians and patients was reduced. In the afterloading procedure, an empty, tubular applicator is inserted into the target volume (e.g., the uterus) before the actual therapy and, after checking the position, loaded with a radioactive preparation. The preparation is located at the tip of a steel wire that is advanced and retracted step by step under computer control. After the pre-calculated time, the source is withdrawn into a safe and the applicator is removed. The procedure is used for breast cancer, bronchial carcinoma or oral floor carcinoma, among others. Beta emitters such as 90Sr or 106Ru or 192Ir are used.
=== Reference materials === Reference materials are compounds which are carefully calibrated against the primary reference or a calibration material. These compounds allow for isotopic analysis of materials differing in chemical or isotopic composition from the compounds defining the isotopic scales on which measurements are reported. In general these are the materials most researchers mean when they say "reference materials". An example of a reference material is USGS-34, a KNO3 salt with a δ15N of -1.8‰ vs. AIR. In this case the reference material has a mutually agreed upon value of δ15N when measured relative to the primary reference of atmospheric N2 (Böhlke et al., 2003). USGS-34 is useful because it allows researchers to directly measure the 15N/14N of NO3− in natural samples against the standard and report observations relative to N2 without having to first convert the sample to N2 gas.
== Veterinary use == Meloxicam is used in veterinary medicine mainly to treat dogs, but also sees off-label use in other animals such as cattle and exotics. In the European Union and other countries it is not considered off-label and can be used in cattle, pigs, horses, dogs, cats and guinea pigs. It has also been investigated as an alternative to diclofenac by the Royal Society for the Protection of Birds (RSPB) to prevent deaths of vultures. Depending on the animal species, each country or union of countries applies different guidelines or legal frameworks for the use of the drug, as well as different recorded side effects. The most common side effects in dogs include gastrointestinal irritation (vomiting, diarrhea, and ulceration). As far as the perioperative administration is concerned, in healthy dogs given meloxicam, no perioperative adverse effects on the cardiovascular system have been reported at recommended dosages. Perioperative administration of meloxicam to cats did not affect postoperative respiratory rate nor heart rate.
Sources: en.wikipedia.org
== Clinical significance == Urothelium is susceptible to carcinoma. Because the bladder is in contact with urine for extended periods, chemicals that become concentrated in the urine can cause bladder cancer. For example, cigarette smoking leads to the concentration of carcinogens in the urine and is a leading cause of bladder cancer. Aristolochic acid, a compound found in plants of the family Aristolochiaceae, also causes DNA mutations and is a cause of liver, urothelial and bladder cancers. Occupational exposure to certain chemicals is also a risk factor for bladder cancer. This can include aromatic amines (aniline dye), polycyclic aromatic hydrocarbons, and diesel engine exhaust.
Abdomen and obliques (belly) Crunch (i) Leg raise (c) Russian twist (c) Sit-up (c) Biceps (front of upper arms) Biceps curl (i) Pull ups with a supinated grip Calves Calf raise (i) Deltoids (shoulders) Front raise (i) Head stand into Handstand push-up (c) Lateral raise (i) Military press (c) Rear delt raise (i) Shoulder press (c) Upright row (c) Forearms Wrist curl (i) Wrist extension (i) Hamstrings (back of thighs) Deadlift (c) Frog jumping (i) Good-morning (exercise) (c) Leg curl (i) Squat (c) Lats and trapezius (back) Bent-over row (c) Chin-up (c) Pulldown (c) Pullup (c) Seated row (c) Shoulder shrug (i) Supine row (c) Lower back Deadlift (c) Good-morning (exercise) (c) Hyperextension (c) Pectorals (chest) Bench press (c) Chest fly (i) Dips (c) Machine fly (i) Push-up (c) Pelvis Vaginal weightlifting Quadriceps (front of thighs) Frog Jumping (i) Leg extension (i) Leg press (c) Lunge (c) Squat (c) Triceps (back of upper arms) Close-grip bench press (c) Dips (c) Push-down (exercise) (i) Lying triceps extensions (i)
==== New Zealand ==== This is known as creaming soda, ice cream soda, chill drink, or cream soda, though the flavor changes are negligible. It is usually a bright yellow colour or a white opaque. It is one of the many flavors sold by Foxton Fizz. It is also one of the many carbonated drink-flavors offered by Golden Circle.
Maximum temperatures rather than minimum temperatures influence the weight of hatchlings unless the minimum temperature exceeds the tolerance limit. In later hatchlings warmer weather and decreased food availability promotes more rapid development resulting in a smaller body size compared to earlier hatchlings. The heaviest hatchlings come from colder habitats. Increased population density also results in decreased adult size as well as slower development.
Tryptamines: N-methyltryptamine (NMT) (isomer of AMT) and methylisopropyltryptamine (MiPT) (isomer of DET) Methoxytryptamines: 4-MeO-DMT (isomer of 5-MeO-DMT) and 5-MeO-DPT (isomer of 5-MeO-DiPT) Hydroxytryptamines: 6-HO-DMT and 7-HO-DMT (both isomers of psilocin (4-HO-DMT)) Phenethylamines: Scalines: escaline (isomer of TMA) 2Cs: 2C-G (isomer of 2C-E and DOM) Amphetamines: DOx TMA-2 (2,4,5-TMA) (isomer of TMA), Aleph-2 (isomer of 2C-T-4), and Aleph-4 (isomer of 2C-T-7) 4Cs: Ariadne (isomer of DOET) MDxx: MBDB (isomer of MDEA Others: TMA-6 (2,4,6-TMA) (isomer of TMA) Others have not been explicitly noted by the United States DEA but may also be considered. Examples include the DET isomers MPT and MiPT and the LSD isomers MiPLA and LAMPA, among others.
Sources: en.wikipedia.org
== History == Electron-capture dissociation was developed by Roman Zubarev and Neil Kelleher while in Fred McLafferty's lab at Cornell University. Irradiation of melittin 4+ ions and ubiquitin 10+ ions (trapped in FT-MS cell) by laser pulses not only resulted in peculiar c', z fragmentation but also charge reduction. It was suggested that if FT cell is modified to trap cations and electrons simultaneously, secondary electrons emitted by UV photons increases the charge reduction effect and c′, z• fragmentation. Replacing UV laser with EI source led to the development of this new technique.
== Uses == Polymersomes that contain active enzymes and that provide a way to selectively transport substrates for conversion by those enzymes have been described as nanoreactors. Polymersomes have been used to create controlled release drug delivery systems. Similar to coating liposomes with polyethylene glycol, polymersomes can be made invisible to the immune system if the hydrophilic block consists of polyethylene glycol. Their permeability can be modulated by exogenous factors, for example by incorporation of stimuli-responsive molecules such as photoswitches, or pH responsive groups. Thus, polymersomes are useful carriers for targeted drug delivery. For in vivo applications, polymersomes are de facto limited to the use of FDA-approved polymers, as most pharmaceutical firms are unlikely to develop novel polymers due to cost issues. Fortunately, there are a number of such polymers available, with varying properties, including: Hydrophilic blocks
16 August – A university reports the release of 'Quad-SDK' which may be the first open source full-stack software for large agile four-legged robots, compatible with the ROS. 17 August A report by Global Forest Watch, using new data, concludes that the amount of tree cover being burned has nearly doubled in the past 20 years. The Nadir crater, likely the result of a second, smaller asteroid that struck around the same time as the Chicxulub impact, is identified and described by researchers. Geologists warn that the world is "woefully underprepared" for a massive volcanic eruption. They estimate a one-in-six chance of a magnitude seven explosion in the next one hundred years. Researchers report the development of floating artificial leaves for light-driven hydrogen and syngas fuel production. The lightweight, flexible devices are scalable and can float on water similar to lotus leaves.
=== Branched polymers === A monomer with functionality of 3 or more will introduce branching in a polymer and will ultimately form a cross-linked macrostructure or network even at low fractional conversion. The point at which a tree-like topology transits to a network is known as the gel point because it is signalled by an abrupt change in viscosity. One of the earliest so-called thermosets is known as Bakelite. It is not always water that is released in step-growth polymerization: in acyclic diene metathesis or ADMET, dienes polymerize with loss of ethene.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.